PT - JOURNAL ARTICLE AU - Imsuwansri, Thanarath AU - Jongthitinon, Thitinan AU - Pojdoung, Niramon AU - Meesiripan, Nuntana AU - Sakarin, Siriwan AU - Boonkrai, Chatikorn AU - Wongtangprasert, Tossapon AU - Phakham, Tanapati AU - Audomsun, Thittaya AU - Attakitbancha, Chadaporn AU - Saelao, Pijitra AU - Muanwien, Phijitra AU - Tian, Maoxin Tim AU - Tongchusak, Songsak AU - Sangruji, Bhrus AU - Wannigama, Dhammika Leshan AU - Sawangmake, Chenphop AU - Rodprasert, Watchareewan AU - Le, Quynh Dang AU - Purbantoro, Steven Dwi AU - Vasuntrarak, Kananuch AU - Nantavisai, Sirirat AU - Sirilak, Supakit AU - Uppapong, Ballang AU - Sapsutthipas, Sompong AU - Trisiriwanich, Sakalin AU - Somporn, Thitiporn AU - Usoo, Asmah AU - Mingngamsup, Natthakarn AU - Phumiamorn, Supaporn AU - Aumklad, Porawan AU - Arunprasert, Kwanputtha AU - Patrojanasophon, Prasopchai AU - Opanasopit, Praneet AU - Pesirikan, Norapath AU - Nitisaporn, Ladda AU - Pitchayakorn, Jesada AU - Narkthong, Thana AU - Mahong, Bancha AU - Chaiyo, Kumchol AU - Srisuthisamphan, Kanjana AU - Viriyakitkosol, Ratchanont AU - Aeumjaturapat, Songklot AU - Jongkaewwattana, Anan AU - Bunnag, Sakarn AU - Pisitkun, Trairak TI - A randomized, placebo-controlled trial of a nasal spray solution containing broadly potent neutralizing antibodies against SARS-CoV-2 variants in healthy volunteers AID - 10.1101/2022.10.04.22280574 DP - 2022 Jan 01 TA - medRxiv PG - 2022.10.04.22280574 4099 - http://medrxiv.org/content/early/2022/10/05/2022.10.04.22280574.short 4100 - http://medrxiv.org/content/early/2022/10/05/2022.10.04.22280574.full AB - Successful COVID-19 prevention requires additional measures beyond vaccination, social distancing, and masking. A nasal spray solution containing human IgG1 antibodies against SARS-CoV-2 (COVITRAP™) was developed to strengthen other COVID-19 preventive arsenals. Here, we evaluated its pseudovirus neutralization potencies, preclinical and clinical safety profiles, and intranasal SARS-CoV-2 inhibitory effects in healthy volunteers (NCT05358873). COVITRAP™ exhibited broadly potent neutralizing activities against SARS-CoV-2 with PVNT50 values ranging from 0.0035 to 3.1997 μg/ml for the following variants of concern (ranked from lowest to highest): Alpha, Beta, Gamma, Ancestral, Delta, Omicron BA.1, Omicron BA.2, Omicron BA.4/5, and Omicron BA.2.75. It demonstrated satisfactory preclinical safety profiles based on evaluations of in vitro cytotoxicity, skin sensitization, intracutaneous reactivity, and systemic toxicity. Its intranasal administration in rats did not yield any detected circulatory levels of the human IgG1 anti-SARS-CoV-2 antibodies at any time point during the 120 hours of follow-up. A double-blind, randomized, placebo-controlled trial (RCT) was conducted on 36 healthy volunteers who received either COVITRAP™ or a normal saline nasal spray at a 3:1 ratio. Safety of the thrice-daily intranasal administration for 7 days was assessed using nasal sinuscopy, adverse event recording, and self-reporting questionnaires. COVITRAP™ was well tolerated, with no significant adverse effects in healthy volunteers for the entire 14 days of the study. The intranasal SARS-CoV-2 inhibitory effects of COVITRAP™ were evaluated in nasal fluids taken from volunteers pre- and post-administration using a SARS-CoV-2 surrogate virus neutralization test. SARS-CoV-2 inhibitory effects in nasal fluids collected immediately or six hours after COVITRAP™ application were significantly increased from baseline for all three variants tested, including Ancestral, Delta, and Omicron BA.2. In conclusion, COVITRAP™ was safe for intranasal use in humans to provide SARS-CoV-2 inhibitory effects in nasal fluids that lasted at least six hours. Therefore, COVITRAP™ can be considered an integral instrument for COVID-19 prevention.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05358873Funding StatementThis study was sponsored by HIBIOCY Co., Ltd., and funded by the Program Management Unit Competitiveness (PMU-C) [Grant No. C10F650051], Ministry of Higher Education, Science, Research and Innovation, Thailand.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of the Department of Medical Services, Ministry of Public Health, Thailand gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.